Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience
ACS Medicinal Chemistry Letters August 21, 2024 DOI: 10.1021/acsmedchemlett.4c00412 via OpenAlex
Summary
AI-generated from the abstractA review of three patent applications examines the potential of entheogens such as psilocybin to treat cognitive decline and bolster psychological resilience in patients receiving anesthesia or sedation. The article describes proposed therapeutic mechanisms, treatment methods, and possible clinical outcomes for postoperative care. It provides an overview of this emerging approach without presenting original data or empirical findings.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Keywords | Surgical-medicine Mental-health Cognitive-function Psychedelics Neuroscience |
| Key finding | Entheogens like psilocybin may offer a novel approach to mitigating cognitive decline and enhancing psychological resilience in patients undergoing anesthesia and sedation. |
Abstract
Recent advancements in medical research have focused on the utilization of entheogens, particularly psilocybin and its related compounds, as therapeutic agents in mitigating cognitive decline and enhancing psychological resilience in patients undergoing anesthesia and sedation. This Patent Highlight integrates findings from three patent applications, each contributing unique insights into the potential applications of these substances in medical settings. The article examines the therapeutic mechanisms, proposed treatment methods, and potential clinical outcomes, offering an overview of this innovative approach to postoperative care.